Jun 2026 (Q2 FY26) — Aug 4, 2026
AdaptHealth Q2 FY26 — Strategic Portfolio Streamlining Amidst Capitated Contract Challenges
Read the full callAdaptHealth (AHCO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
AdaptHealth earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 740 | +12.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -18.6 | −28.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -134 | −1012.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$6.39 +2.24% · +$0.14
Performance −29.3% 1Y
1Y: $9.04 on 14 Oct 2025 → $6.39. High $13.38 (28 Apr 2026), low $5.22 (10 Aug 2026).
- Previous close
- $6.25
- 52-week range
- $5.22 – $13.38
- One year
- −30.54%
Overview
- Symbol
- AHCO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
AdaptHealth earnings calls (AHCO)
Financials
What the filings say
Net profit, year on year: −1013% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 806 | 857 | 778 | 657 | 820 | 846 | 820 | 740 |
| Expenses | 742 | 759 | 755 | 624 | 759 | 920 | 814 | 884 |
| Operating profit | 63 | 98 | 23 | 66 | 62 | -73 | 5 | -138 |
| Operating margin | 7.9% | 11.4% | 3.0% | 10.0% | 7.5% | −8.7% | 0.7% | −18.6% |
| Interest | 31 | — | — | — | — | — | — | — |
| Profit before tax | 32 | 71 | -5 | 38 | 36 | -98 | -20 | -165 |
| Tax rate | 25.2% | 27.3% | −16.3% | 85.9% | 29.2% | −3.6% | 26.0% | 12.8% |
| Net profit | 23 | 50 | -7 | 15 | 25 | -103 | -16 | -134 |
| EPS ($ per share) | 0.16 | — | -0.05 | 0.10 | 0.17 | — | -0.12 | -0.99 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | — | — | 0 | 0 | 0 | 0 | 0 |
| Reserves | -13 | -40 | -199 | -43 | 26 | -653 | -562 | -633 |
| Total liabilities | 266 | 612 | 1,533 | 3,184 | 3,062 | 3,042 | 2,909 | 2,790 |
| Fixed assets | 62 | 64 | 110 | 399 | 487 | 495 | 475 | 503 |
| Total assets | 369 | 547 | 1,813 | 5,250 | 5,220 | 4,509 | 4,487 | 4,317 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 68 | 60 | 196 | 276 | 374 | 481 | 542 | 602 |
| Cash from investing | -96 | -85 | -816 | -1,825 | -411 | -357 | -310 | -303 |
| Cash from financing | 49 | 76 | 643 | 1,599 | -66 | -93 | -199 | -302 |
| Net cash flow | 21 | 52 | 23 | 50 | -103 | 31 | 33 | -4 |
| Capital expenditure | -10 | -21 | -40 | -203 | -391 | -337 | -306 | -382 |
| Free cash flow | 58 | 39 | 156 | 72 | -18 | 143 | 236 | 219 |
Insider filings
42 filings between Dec 4, 2025 and Sep 9, 2026.
Open market
decisions to buy or sellPurchases
$49.21M
15 purchases by 5 insiders
Sales
$278.3K
3 sales by 2 insiders
67% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 21
- Award — granted as compensation
- 1
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| CASHIN RICHARD M JR | $24.35M | — | Mar 20, 2026 |
| OEP VII GP, L.L.C. | $24.35M | — | Mar 20, 2026 |
| WOLF DALE B | $314.9K | — | Aug 7, 2026 |
| Schuster III Russell E. | — | $231.1K | Jul 1, 2026 |
| SAMET KENNETH A | $149.9K | — | Aug 6, 2026 |
| Williams David Solomon III | — | $47.1K | Dec 4, 2025 |
| Rew Richard W. II | $44.5K | — | Feb 26, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2026 | CURRIE HARRISS T CHIEF FINANCIAL OFFICER | Award | 141,372 | $0 |
| Aug 7, 2026 | WOLF DALE B Director | Purchase | 20,000 | $117.2K |
| Aug 6, 2026 | WOLF DALE B Director | Purchase | 20,000 | $126.0K |
| Aug 6, 2026 | SAMET KENNETH A Director | Purchase | 23,500 | $149.9K |
| Jul 1, 2026 | Schuster III Russell E. Chief Commercial Officer | Sale 10b5-1 plan | 11,275 | $117.7K |
| Jun 24, 2026 | Connors Terence J Director | Award | 18,999 | $0 |
| Jun 24, 2026 | Weaver Susan T Director | Award | 18,999 | $0 |
| Jun 24, 2026 | Williams David Solomon III Director | Award | 18,999 | $0 |
| Jun 24, 2026 | SAMET KENNETH A Director | Award | 18,999 | $0 |
| Jun 24, 2026 | Lundberg Theodore B. Director | Award | 18,999 | $0 |
| Jun 24, 2026 | SAMET KENNETH A Director | Award | 6,070 | $60.0K |
| Jun 24, 2026 | WOLF DALE B Director | Award | 18,999 | $0 |
| Jun 24, 2026 | Coppens Bradley J Director | Award | 18,999 | $0 |
| Jun 24, 2026 | BELINFANTI GREGORY Director | Award | 18,999 | $0 |
| Jun 1, 2026 | Schuster III Russell E. Chief Commercial Officer | Sale 10b5-1 plan | 11,275 | $113.4K |
| May 27, 2026 | McFadden Daniel Edward Chief Operating Officer | Award | 20,134 | $0 |
| Mar 20, 2026 | OEP VII GP, L.L.C. 10% owner | Purchase | 447,100 | $4.43M |
| Mar 20, 2026 | CASHIN RICHARD M JR 10% owner | Purchase | 447,100 | $4.43M |
| Mar 19, 2026 | OEP VII GP, L.L.C. 10% owner | Purchase | 727 | $7.2K |
| Mar 19, 2026 | CASHIN RICHARD M JR 10% owner | Purchase | 727 | $7.2K |
| Mar 13, 2026 | Prast Albert A. Chief Technology Officer | Tax withheld | 58,203 | $601.2K |
| Mar 12, 2026 | OEP VII GP, L.L.C. 10% owner | Purchase | 689,336 | $6.71M |
| Mar 12, 2026 | CASHIN RICHARD M JR 10% owner | Purchase | 689,336 | $6.71M |
| Mar 11, 2026 | OEP VII GP, L.L.C. 10% owner | Purchase | 536,827 | $5.22M |
| Mar 11, 2026 | CASHIN RICHARD M JR 10% owner | Purchase | 536,827 | $5.22M |
| Mar 10, 2026 | OEP VII GP, L.L.C. 10% owner | Purchase | 820,528 | $7.98M |
| Mar 10, 2026 | CASHIN RICHARD M JR 10% owner | Purchase | 820,528 | $7.98M |
| Mar 5, 2026 | Weaver Susan T Director | Gift | 73,472 | $0 |
| Mar 5, 2026 | Weaver Susan T Director | Gift | 73,472 | $0 |
| Feb 27, 2026 | WOLF DALE B Director | Purchase | 8,000 | $71.7K |
| Feb 26, 2026 | Rew Richard W. II CLO and General Counsel | Purchase | 5,000 | $44.5K |
| Jan 30, 2026 | McFadden Daniel Edward Chief Business Systems Officer | Award | 29,284 | $0 |
| Jan 30, 2026 | Prast Albert A. Chief Technology Officer | Award | 63,449 | $0 |
| Jan 30, 2026 | Clemens Jason A Chief Financial Officer | Award | 126,899 | $0 |
| Jan 30, 2026 | Archbold Christine E. Chief Accounting Officer | Award | 32,213 | $0 |
| Jan 30, 2026 | Foster Suzanne Chief Executive Officer | Award | 329,449 | $0 |
| Jan 30, 2026 | Barnhart Toby Scott Chief Operating Officer | Award | 68,330 | $0 |
| Jan 30, 2026 | Schuster III Russell E. Chief Commercial Officer | Award | 48,807 | $0 |
| Jan 30, 2026 | Rew Richard W. II CLO and General Counsel | Award | 53,688 | $0 |
| Jan 9, 2026 | BELINFANTI GREGORY Director | Award | 11,776 | $0 |
| Jan 9, 2026 | Lundberg Theodore B. Director | Award | 13,740 | $0 |
| Dec 4, 2025 | Williams David Solomon III Director | Sale | 5,000 | $47.1K |
| Aug 22, 2025 | Williams David Solomon III Director | Sale | 8,200 | $79.8K |
| Jun 26, 2025 | WOLF DALE B Director | Award | 21,346 | $0 |
| Jun 26, 2025 | BELINFANTI GREGORY Director | Award | 21,346 | $0 |
| Jun 26, 2025 | BELINFANTI GREGORY Director | Award | 6,740 | $0 |
| Jun 26, 2025 | Weaver Susan T Director | Award | 21,346 | $0 |
| Jun 26, 2025 | Connors Terence J Director | Award | 21,346 | $0 |
| Jun 26, 2025 | Lundberg Theodore B. Director | Award | 21,346 | $0 |
| Jun 26, 2025 | Lundberg Theodore B. Director | Award | 7,864 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AdaptHealth Corp.
Free account. Everything above stays public.
Write why you follow AdaptHealth Corp. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading